Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

FDA grants breakthrough therapy designation to Promacta for first-line use in severe aplastic anemia

Jan. 4, 2018

Portola Pharmaceuticals provides update on BLA for AndexXa

Dec. 27, 2017

Ironwood Pharmaceuticals begins phase II study of IW-1701 in sickle cell disease

Dec. 22, 2017

First patient treated in phase I study of Achillion's ACH-5228

Dec. 22, 2017

Ticagrelor well tolerated in phase II pediatric sickle cell disease trial

Dec. 21, 2017

BioMarin initiates first phase III study of valoctocogene roxaparvovec for severe hemophilia A

Dec. 20, 2017

FDA lifts clinical hold on Alnylam Pharmaceuticals' fitusiran

Dec. 18, 2017

First in vivo results for LSD1 inhibitor show promise for the treatment of SCD

Dec. 15, 2017

Vertex enters development agreement with CRISPR Therapeutics for gene-editing treatment

Dec. 14, 2017

Positive first-in-human data for new complement C3 inhibitor AMY-10

Dec. 14, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...